Dr. Nikhil Khushalani, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Roswell Park Cancer Institute

  Fellowship Hospital

• Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities, 2019-02-19

• An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response, 2021-07-16

• The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy, 2019-08-09

• Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma, 2019-09-12

• The High-Dose Aldesleukin "Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma, 2014-11-25

• Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study, 2021-11-10

• Targeting the IL-2 Inducible Kinase in Melanoma; A Phase 2 Study of Ibrutinib in Systemic Treatment-Refractory Distant Metastatic Cutaneous Melanoma: Preclinical Rationale, Biology, and Clinical Activity (NCI9922), 2021-04-01

• Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma, 2023-06-14

• Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma, 2022-12-15

• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain, 2018-08-23

• Single cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy, 2022-05-13

• A Randomized Phase II Trial of Combined Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy for Advanced Merkel Cell Carcinoma, 2022-09-12

• Development of Targeted Alpha Particle Therapy for Solid Tumors, 2019-11-26

• NCI 8628 - A Randomized Phase II Study of Ziv-aflibercept and High Dose Interleukin-2 (HD IL-2) or HD IL-2 Alone for Inoperable Stage III or IV Melanoma, 2018-10-10

• Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment, 2023-09-19

• The "Great Debate” at Melanoma Bridge 2021, December 2nd-4th, 2021, 2022-05-10

• Malignant adnexal tumors of the skin: a single institution experience, 2018-05-30

• Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities, 2022-09-01

• A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma, 2016-12-20

• Combined BRAF and HSP90 inhibition in patients with unresectableBRAFV600E mutant melanoma, 2018-04-19

• Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma, 2022-03-01

• Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma, 2020-12-19

• Higher than reported adolescent and young adult clinical trial enrollment during the "Golden Age” of melanoma clinical trials, 2018-02-25